Last reviewed · How we verify

Trintellix — Competitive Intelligence Brief

Trintellix (vortioxetine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin modulator and stimulator (SMS); SSRI-like agent. Area: Neuroscience.

marketed Serotonin modulator and stimulator (SMS); SSRI-like agent Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor Neuroscience Live · refreshed every 30 min

Target snapshot

Trintellix (vortioxetine) — Takeda. Vortioxetine enhances serotonergic activity through serotonin reuptake inhibition with additional 5-HT3 antagonism and 5-HT1A agonism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Trintellix TARGET vortioxetine Takeda marketed Serotonin modulator and stimulator (SMS); SSRI-like agent Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor 2013-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin modulator and stimulator (SMS); SSRI-like agent class)

  1. Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trintellix — Competitive Intelligence Brief. https://druglandscape.com/ci/vortioxetine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: